



Self-Reported Hearing Loss, Cognitive Performance, and Risk of MCI: Findings from the Wisconsin Registry for Alzheimer's Prevention



Taylor N. Fields,¹⁻⁴ Rebecca L. Kosciak, PhD,² Kimberly D. Mueller, PhD,^{2,5} Sterling C. Johnson, PhD,^{2,3,6,7} Ozioma C. Okonkwo, PhD,^{2,3,6} and Ruth Y. Litovsky, PhD^{4,5,8}

¹Neuroscience Training Program, ²Wisconsin Alzheimer's Institute, ³Wisconsin Alzheimer's Disease Research Center, ⁴Binaural Hearing and Speech Lab at the Waisman Center, ⁵Dept. of Communication Sciences and Disorders, ⁶Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, ⁷Waisman Laboratory for Brain Imaging and Behavior, ⁸Dept. of Surgery, Division of Otolaryngology

BACKGROUND

- Individuals with **mild cognitive impairment (MCI)**^{1,2} and dementia due to **Alzheimer's disease (AD)**^{2,3} often exhibit auditory dysfunction
- To the extent that these auditory deficits precede MCI/AD diagnosis, they may be a risk factor for impending cognitive decline and incident impairment
- Although there is growing interest in the relationship between hearing and cognition in cognitively healthy individuals, most longitudinal studies have involved elderly adults^{4,5}
- The protracted disease course of AD highlights the importance of identifying early risk factors that may increase the likelihood of developing impairments later in life

OBJECTIVES

- Determine the prevalence of **self-reported diagnosed hearing loss (dxHL)** in a cognitively healthy, late middle-aged cohort at risk for AD
- Evaluate whether dxHL at baseline is associated with poorer prospective cognitive performance and increased incidence of MCI at follow-up five years later

METHODS

Participants:

- N = 783 cognitively healthy, late middle-aged adults enrolled in the Wisconsin Registry for Alzheimer's Prevention (**WRAP**, see **Table 1**)
- At baseline, participants reported whether they had ever been diagnosed with hearing loss as part of a medical history questionnaire

Clinical and Neuropsychological Assessment

- Diagnosis of MCI rendered via multidisciplinary consensus conference
- Cognitive tests of interest:
 - Trail Making Tests A & B (**psychomotor speed and mental flexibility**)
 - WAIS-R Digit Symbol Substitution Test (**set switching**)
 - Mini Mental State Exam (**global cognitive functioning**)

Statistical Analyses

- Frequency distribution to assess prevalence of self-reported dxHL at baseline
- Linear regression to assess relationship between baseline hearing status and cognitive performance at baseline and follow-up visits
- Logistic regression to estimate risk of incident MCI as a function of baseline hearing status
- Both regressions were adjusted for age, sex, education, and baseline/follow-up interval

FIGURES & TABLES

Table 1. Participant characteristics at baseline.

Characteristic	no dxHL (n = 711, 90.8%)	dxHL (n = 72, 9.2%)
Baseline age, y, mean (SD)	57.6 (6.4)	61.0 (5.8)
Follow-up interval, y, mean (SD)	4.9 (0.7)	4.8 (0.6)
Standardized reading score, mean (SD)	107.9 (8.8)	110.6 (7.5)^a
Female, %	74.0	55.6^b
APOE ε4+, %	38.1	38.9

^aMann-Whitney U test, p<.05; ^bPearson chi-squared test, p<.05

Figure 1. Main effect of baseline hearing status on cognitive performance.






Figure 2. Main effect of baseline hearing status on risk of incident MCI



RESULTS & DISCUSSION

- Prevalence of self-reported diagnosed hearing loss (dxHL) at baseline was 9.2% (**Table 1**)
 - Considerably lower than hearing loss prevalence (~30%) reported previously for this age group,⁶ likely due to self-report method
 - Suggests *observed effects may be under-estimated and highlights the importance of obtaining objective auditory measures in this population in the future*
- Individuals with dxHL at baseline performed significantly poorer on multiple tests of speed and flexibility (**Figure 1A-C**) and global cognition (**Figure 1D**) at follow-up
 - However, group performance also differed on several measures at baseline (**Figure 1B,C**)
 - Further analysis required to determine whether *rate of decline* also differs between groups
- dxHL at baseline was associated with an over two-fold increased risk of incident MCI at follow-up (**Figure 2**)

CONCLUSIONS

- Hearing loss among cognitively healthy, late middle-aged adults was prospectively associated with poorer cognitive performance and more than double the risk of developing MCI over 5 years
- Results add to growing body of evidence that hearing loss may be a risk factor for MCI and thus identifying and treating hearing loss may help reduce the burden of AD
- Further studies, using objective auditory measures and biomarkers of AD pathology, will be necessary to clarify the nature of these associations

REFERENCES & ACKNOWLEDGEMENTS

- Rahman, T. T. A., Mohamed, S. T., Albanouby, M. H., Bekhet, H. F. (2011) Central auditory processing in elderly with mild cognitive impairment. *Geriatr Gerontol Int*, 11: 304-308.
- Idrizbegovic E., Hederstierna C., Dahlquist M., Nordström C.K., Jelic V., Rosenhall U. (2011) Central auditory function in early Alzheimer's disease and in mild cognitive impairment. *Age Ageing*, 40:249-254.
- Strouse, A. L., Hall III, J. W., Burger, M. C. (1995) Central auditory processing in Alzheimer's disease. *Ear Hear*, 16: 230-238.
- Lin, F. R., Yaffe, K., Xia, J., et al. (2013) Hearing loss and cognitive decline in older adults. *JAMA Internal Medicine*, 173(4): 293-299.
- Gates, G. A., Anderson, M. L., McCurry, S. M., Feeney, M. P., Larson, E. B. (2011) Central auditory dysfunction as a harbinger of Alzheimer dementia. *Arch Otolaryngol Head Neck Surg*, 137(4): 390-395.
- Lin, F. R., Niparko, J. K., Ferrucci, L. (2011) Hearing loss prevalence in the United States. *Arch Intern Med*, 171(20): 1851-1852.

WRAP is supported by NIA grants R01AG27161 (Wisconsin Registry for Alzheimer Prevention: Biomarkers of Preclinical AD) Helen Bader Foundation, Northwestern Mutual Foundation, Extencicare Foundation and State of Wisconsin, and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. This work was also supported by NRSA (T32 GM007507 to TNF).